Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome

Sleep Medicine

Volumn 9, Issue 7, 2008, Pages 715-726

  Quilici, S ^a   Abrams, K R ^b   Nicolas, A ^c   Martin, M ^a   Petit, C ^d   LLeu, P L ^d   Finnern, H W ^e  

^a i3 Innovus ^*  (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c CENTRE HOSPITALIER LE VINATIER   (France)

^d BOEHRINGER INGELHEIM   (France)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Efficacy; Meta analysis; Non ergot dopamine agonists; Pramipexole; Restless legs syndrome; Safety

Indexed keywords

PLACEBO; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; BAYES THEOREM; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; INCIDENCE; INSOMNIA; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCORING SYSTEM; SOMNOLENCE; STATISTICAL MODEL; SYSTEMATIC REVIEW; VOMITING;

BENZOTHIAZOLES; DOPAMINE AGONISTS; DRUG TOXICITY; HUMANS; INDOLES; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME;

EID: 49849101615     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2007.11.020     Document Type: Article

References (57)

1. National Center on Sleep Disorders Research, National Heart Lung and Blood Institute National Institutes of Health. Restless legs syndrome: detection and management in primary care. 00-3788; 2000. NIH publication.
2. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19.
3. Rothdach A.J., Trenkwalder C., Haberstock J., Keil U., and Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and morbidity in Augsburg elderly. Neurology 54 (2000) 1064-1068
4. Allen R., Walters A., Montplaisir J., Hening W., Myers A., Bell T.J., et al. Restless legs syndrome prevalence and impact, REST general population study. Arch Intern Med 165 (2005) 1286-1292
5. Hening W., Walters A.S., Allen R.P., Montplaisir J., Myers A., and Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 5 (2004) 237-246
6. Allen R.P., and Earley C.J. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 18 (2001) 128-147
7. Michaud M., Dumont M., Selmaoui B., Paquet J., Fantini M.L., and Montplaisir J. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol 55 (2004) 372-380
8. Oertel W.H., Trenkwalder C., Zucconi M., Benes H., Borreguero D.G., Bassetti C., et al. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 22 S18 (2007) S466-S475
9. European Medicines Agency (EMEA). Available from: , [last accessed 20-12-2007].
10. U.S. Food and Drug Administration (FDA). Available from: , [last accessed 20-12-2007].
11. GSK. Available from: , [last accessed 20-12-2007].
12. Walters A.S., LeBrocq C., Dhar A., Hening W., Rosen R., Allen R.P., et al. Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med 4 (2003) 121-132
13. National Institute of Mental Health. 028 CGI clinical global impressions. In: Guy W, editor. ECD-EU assessment for psychopharmacology. Rev. ed. Rockville, MD: National Institute of Mental Health; 1976. p. 217-22.
14. Whitehead A. Combining Estimates of a Treatment Difference Across Trials. Meta-Analysis of Controlled Clinical Trials. Wiley; 2003. p. 57-98.
15. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
16. Lu G., and Ades A.E. Mixed treatment comparisons: combination of direct and indirect evidence. Stat Med 23 (2004) 3105-3124
17. Caldwell D.M., Ades A.E., and Higgins J.P.T. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331 (2005) 897-900
18. Spiegelhalter DJ, Thomas A, Best N, Lunn D. WinBUGS Users Manual, version 1.4.1. Cambridge: MRC Biostatistics Unit; 2004.
19. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials & Health-Care Evaluation. Chichester: John Wiley and Sons; 2003. ISBN: 0 71 49975 7.
20. European Medicine Agency (EMEA). Guideline on the choice of non-inferiority margin. Available from: www.emea.europa.eu/pdfs/human/ewp/215899en.pdf; 2005 [last accessed 20-12-2007].
21. Transparency commission. Recommendation of the commission ADARTREL. Available from: http://www.has-sante.fr/portail/types/FileDocument/cloxiti.jsp?id=c_2454 84; 2004 [last accessed 20-12-2007].
22. AFSSAPS. ADARTREL, VENUXIN, ZIPEREVE 0.25 mg, 0.5 mg, 1 mg or 2 mg, comprimé pelliculé. Rapport public d'évaluation. Available from: ; 2004 [last accessed 01.10.04].
23. Scottish Medicines Consortium. Re-submission, Ropinirol Tablets (Adartrel®). 10.2.06. Available from: http://www.scottishmedicines.org.uk/smc/5038.html, NHS, Scotland [last accessed 20-12-2007].
24. Scottish Medicines Consortium. Pramipexole salt 0.125 mg, 0.250 mg, 1.0 mg, Tablets (Mirapexin®). 10.03.06. Available from: http://www.scottishmedicines.org.uk/smc/4382.html, NHS, Scotland [last accessed 20-12-2007].
25. Sutton A.J., and Abrams E.J. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 10 (2001) 277-303
26. Saletu M., Anderer P., Saletu-Zyhlarz G., Hauer C., and Saletu B. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci 252 (2002) 185-194
27. Montplaisir J., Nicolas A., Denesle R., and Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 52 (1999) 938-943
28. Montplaisir J., Denesle R., and Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 7 1 (2000) 27-31
29. Partinen M., Hirvonen K., Jama L., Alakuijala A., Hublin C., Tamminen I., et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study-The PRELUDE study. Sleep Med 7 (2006) 407-417
30. Bogan R.K., Fry J.M., Schmidt M.H., Carson S.W., and Ritchie S.Y. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 81 (2006) 17-27
31. Abetz L., Arbuckle R., Allen R.P., Mavraki E., and Kirsch J. The reliability, validity and responsiveness of the restless legs syndrome quality of life questionnaire (RLSQoL) in a trial population. Health Qual Life Outcomes 3 (2005) 79
32. Bliwise D.L., Freeman A., Ingram C.D., Rye D.B., Chakravorty S., and Watts R.L. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 6 (2005) 141-147
33. Allen R.P., Becker P.M., Bogan R., Schmidt M., Kushida C.A., Fry J.M., et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 27 (2004) 907-914
34. Walters A.S., Ondo W.G., Dreykluft T., Grunstein R., Lee D., and Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 19 (2004) 1414-1423
35. Cheer S.M., Bang L.M., and Keating G.M. Ropinirole: for the treatment of restless legs syndrome. CNS Drugs 18 (2004) 747-754
36. Adler C.H., Hauser R.A., Sethi K., Caviness J.N., Marlor L., Anderson W.M., et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 62 (2004) 1405-1407
37. Trenkwalder C., Garcia-Borreguero D., Montagna P., Lainey E., de Weerd A.W., Tidswell P., et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75 (2004) 92-97
38. Saletu B., Gruber G., Saletu M., Brandstatter N., Hauer C., Prause W., et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 41 (2000) 181-189
39. Saletu M., Anderer P., Saletu B., Hauer C., Mandl M., Oberndorfer S., et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 41 (2000) 190-199
40. GlaxoSmithKline Clinical Trial Register. SKF-101468/249 (2005), SKF-101468/190 (2005), SKF-101468/194 (2005), SKF-101468/191 (2005), SKF-101468/188 (2005), RRL100013 (2006), ROP101892 (2005) RRL100310 (2006), SKF-101468/192 (2005), SKF-101468/243 (2005), SKF-101468/207 (2005), SKF-101468/218 (2005). Available from: ; 2005 [last accessed 20-12-2007].
41. Winkelman J.W., Sethi K.D., Kushida C.A., Becker P.M., Koester J., Cappola J.J., et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 67 (2006) 1034-1039
42. Oertel W.H., Stiasny-Kolster K., Bergtholdt B., Hallström Y., Albo J., Leissner L., Schindler T., Koester J., Reess J., and for the pramipexole RLS study group. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (Effect-RLS study). Mov Disord 22 2 (2007) 213-219
43. Trenkwalder C., Stiasny-Kolster K., Kupsch A., Oertel W.H., Koester J., and Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 21 (2006) 1404-1410
44. Trenkwalder C., Kohnen R., Allen R.P., Benes H., Ferini-Strambi L., Garcia-Borreguero D., et al. Clinical trials in restless legs syndrome-Recommendations of the European RLS study group (EURLSSG). Mov Disord 22 S18 (2007) S495-S504
45. Oertel W.H., Trenkwalder C., Zucconi M., Benes H., Borreguero D.G., Bassetti C., et al. State of the art in restless legs syndrome therapy: Practice recommendations for treating restless legs syndrome. Mov Disord 22 S18 (2007) S466-S475
46. Hening WA. Current guidelines and standards of practice for restless legs syndrome. Am J Med 120 1, Suppl. 1 (2007) S22-S27
47. Montagna P. The treatment of restless legs syndrome. Neurol Sci 28 1 (2007) S61-S66
48. Available from: , [last accessed 20-12-2007].
49. Song F., Altman D.G., Glenny A.M., and Deeks J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326 (2003) 472
50. Marx A., and Bucher H.C. Numbers needed to treat derived from meta-analysis: a word of caution. ACP J Club 138 (2003) A11-A12
51. Garcia-Borreguero D, Bogan R, Ritchie SY. Ninth Congress of the EFNS Athens, September 17-20; 2005. p. 2200.
52. Spiegelhalter D., Best N., Carlin B., and van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B 64 (2002) 583-639
53. Lu G., and Ades A.E. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 101 (2006) 447-459
54. Marshall E.C., and Spiegelhalter D.J. Approximate cross-validatory predictive checks in disease mapping models. Stat Med 22 (2003) 1649-1660
55. Ondo W., Romanyshyn J., Dat Vuong K., and Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 61 (2004) 1393-1397
56. Sutton A.J., Song F., Gilbody S.M., and Abrams K.R. Modelling publication bias in meta-analysis: a review. Stat Methods Med Res 9 5 (2000) 421-445
57. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188